Myeloma
Oncology
2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
DS
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
TevaOral CEP-701
Daiichi SankyoDS-3032b
Clinical Trials (2)
Total enrollment: 14 patients across 2 trials
Efficacy and Safety of Oral CEP-701 for the Treatment of Patients With Advanced Multiple Myeloma
Start: Apr 2006Est. completion: May 2007
Phase 2Terminated
Ascending Dose and Exploratory Expansion Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Relapsed and/or Refractory Multiple Myeloma
Start: Aug 2016Est. completion: Nov 201914 patients
Phase 1Terminated
Related Jobs in Oncology
Cell Therapy Account Manager（北陸）
Gilead Sciences
Japan - Tokyo
Just now
Senior Director of Clinical Operations
Arvinas
Remote
2h ago
Specialist, Quality Assurance
Umoja Biopharma
Louisville, Colorado, United States
3h ago
$85K - $105K/yr
Senior Facilities Technician
Umoja Biopharma
Louisville, Colorado, United States
3h ago
Leo Cancer Care: Senior In-House Counsel/General Counsel
Leo Cancer Care
Middleton, Wisconsin
7h ago
Summer Intern - Computational Chemistry & Artificial Intelligence
Arvinas
Remote
9h ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space